Skip to main content

Bispecific Antibodies Poised to Be the Next Major Advance in Oncology

 Human monoclonal antibody therapies, which embrace over 570 agents in the clinical field, have become one of the fastest-growing cancer treatments. Now, a novel therapy based on bispecific antibodies may be a further refinement in oncology treatment that overcomes the limitations of current monoclonal antibody therapies.

 

What are Bispecific Antibodies?

 

Bispecific antibodies (BsAbs) are engineered proteins that can simultaneously recognize and bind two separate and unique targets (antigens or different epitopes of the same antigen). Given the fact of dual functionalities, BsAbs are different from normal monoclonal antibodies.

 

Therapeutics and drugs based on bispecific antibodies are expected to be the next big advance in oncology, hematology in particular. Different from cytotoxic chemotherapy or targeted agents, the distinct mechanism of action of bispecific antibody drugs may enable patients to fight against cancers with the immune system.

 

The Development of Bispecific Antibodies Therapeutics

 

Experts agreed that bispecific antibodies have the potential to impact the treatment of lymphoma and other hematologic malignancies, and thus hundreds of next-generation bispecific antibodies are in clinical trials and at least 2 therapeutics have been approved in the United States.

 

A report released by Kuick Research indicates that the global market for bispecific antibody therapeutics is predicted to reach over $10 billion by 2026.

 

Creative Biolabs has been dedicated to the development of bispecific antibodies for years and is always at the forefront place. A comprehensive list of bispecific antibody products and services are available harnessing its cutting-edge platforms and methods. Up to now, this company can perform BsAb designing, engineering, analyzing, purifying, and manufacturing with trustworthy quality.

 

Bispecific Antibodies Design

 

As previously pointed out, BsAbs are artificially designed molecules, which enhance the difficulties in development at the early stage. Fortunately, now service providers can design customized bispecific antibodies according to research target and clinical practice. For instance, Creative Biolabs helps researchers design bispecific antibodies targeting different epitopes, ligands, receptors, and immune cells.

 

Over 60 BsAbs now have been designed and widely applied to cancer, inflammatory, autoimmune, and other diseases. Other bispecific antibody designs may be based on different modes of action and therapeutic applications, including oncology, hematology, immunology, ophthalmology, and radio-immunotherapy.

 

Bispecific Antibodies Engineering

 

Chemical conjugation, hybrid hybridomas, and genetic engineering have made it possible to adjust the properties of BsAbs such as valency, size, half-life, and flexibility when specific requirements occur. Bispecific IgGs are one of the results of BsAbs engineering, keeping the general size and structure of a normal IgG as well as serum high stability, half-life, and tissue penetration.

 

Other services of bispecific antibody development in the market include bispecific antibody purification to improve efficacy, bispecific antibody analysis for qualified preclinical results, and bispecific antibody manufacturing to satisfy the great need of therapeutic proteins.

 

Clinical Trial Results of Bispecific Antibody Development

 

New data of several agents were presented at the 2020 American Society of Hematology (ASH) annual meeting. Mosunetuzumab and glofitamab, which are T-cell-engaging bispecific antibodies designed to bind to the cancer cell and the T cell simultaneously, show promising effects on patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL).

 

Some experts also believe that mosunetuzumab may be hopeful for patients who cannot tolerate immunochemotherapy and is specifically potential in earlier treatment settings.

 

Though bispecific antibodies are prone to advance oncology treatment because of those encouraging therapeutic studies, the side effects such as toxicity, cytokine release syndrome (CRS), and lack of significant tumor response also deserve more attention in bispecific antibody research. Modification of binding specificity and engineering bispecific antibodies may help the proteins exert better influence in oncology.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

How Haptens Differ from Antigens and Become Immunogens?

The  difference between antigens vs. haptens  is one the most concerning issues for people who are not familiar with them. As a matter of fact, antigens and haptens are similar in many ways. They are both molecules triggering immune responses and acting as antigenic agents. And they both work as immunogens and bind to antibodies although haptens in a different manner.   What distinguishes an antigen mostly from a hapten is that antigens are complete molecules spontaneously triggering immune response whereas haptens are fragmentary small molecules that are unable to elicit immune responses unless they are conjugated to a larger molecule, known as a carrier.   What are Antigens? Antigen s, including proteins, peptides, and polysaccharides, are immunogen   molecules  that can trigger immune response s or naturally bind to   immune   components . An antigen may have one or more epitopes, which are the determinants of recognition and binding to antibod...
Post a Comment
Read more

Review: Creative Biolabs' Model-org Antibodies Fluorescently Labeling Services

Model organisms (Model-org) are non-human species, from which researchers can get insights into other organisms in biological research processes. Various model organism species such as zebrafish, flies, yeast, and rice, greatly contribute to the basic and clinical research in animal husbandry, fishery ， agriculture, forestry, etc.   Investigations on model organisms can be aided by antibody labeling when samples of interest need to be detected, isolated, or purified, though the selection of a proper label can be a challenge.   To select the best antibody labeling way for our Model-org project, we then found Creative Biolabs, one of the most well-established CROs for antibody development. After a comprehensive discussion and consultancy with the scientists at Creative Biolabs, fluorescent tags were  suggested based on our research direction. Fluorescent labels are directly conjugated to the antibody of interest, indicating that we can directly detect the number of fluoresc...
Post a Comment
Read more

Metagenomics Enhances Infectious Disease Surveillance

  Infectious lower respiratory diseases and diarrheal diseases are the leading causes of death globally . And the ongoing COVID-19 pandemic, which has contributed to 4.1 million deaths in 2019, once again is reminding the necessity of proactively identifying early signs of infectious disease outbreaks before things are getting worse. Conventional microbial diagnostics techniques would identify pathogens under specific culture conditions by serological detection of pathogen-associated antibodies or microbial genetic investigation using PCR, but these methods have been seen obvious shortcomings in pathogen coverage. It's highly required to find advanced scientific tools that are more sensitive even with a low microbial load or when targeted microorganisms are not suitable for  in vitro  culture, for which metagenomic approaches that can profile all DNA or RNA of a patient sample are increasingly catching the eyes of researchers.   How metagenomics can be used in infect...
Post a Comment
Read more